EMA Recommends Extension of Therapeutic Indications for Ponatinib By Ogkologos - February 27, 2026 198 0 Facebook Twitter Google+ Pinterest WhatsApp Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Immunotherapy Combination That Targets TIGIT Receptor Shows Promise in Non-Small Cell... December 19, 2022 Pembrolizumab Continues to Demonstrate Durable Efficacy with No New Safety Signals... January 17, 2023 ESMO’s Expert Consensus: Do Not Discontinue or Delay Cancer Treatment That... July 31, 2020 Marginal Benefit in Overall and Progression-Free Survival from New Anticancer Drugs August 12, 2022 Load more HOT NEWS FDA Approves Pembrolizumab with Chemotherapy for Biliary Tract Cancer Few People with Cancer Undergo Testing for Inherited Gene Mutations Trial Highlights Complexities of Targeted Therapy for Pancreatic Cancer FDA Approves Pembrolizumab for Advanced Oesophageal or Gastro-Oesophageal Carcinoma
